“…These molecular descriptors (MDs) were successfully used in the modeling of numerous bioactivities such as: affinity to the dopamine D 2 receptor subtype (Freitas, Brown, & Martins, 2005), glycogen synthase kinase 3 (GSK-3) inhibitors (Goodarzi, Freitas, & Jensen, 2009), antimalarials (Cormanich, Freitas, & Rittner, 2011;Goodarzi & Freitas, 2011), anxiolytic agents receptor antagonists] (Bitencourt & Freitas, 2008), HIV reverse transcriptase inhibitors (Freitas, 2006;Goodarzi & Freitas, 2008;Goodarzi & Freitas, 2010a), phosphodiesterase type 5 (PDE-5) inhibitors (Antunes, Freitas, & Rittner, 2008), antifungals , peptides for treatment of dengue (Silla et al, 2011), anti-inflammatory agents (Lloret et al, 2009) and acetylcholinesterase inhibitors (Bitencourt, Freitas, & Rittner, 2012), among others. The traditional MIA-QSAR descriptors did not only find utility in the modeling of bioactivity endpoints; applications in spectroscopy (in the prediction of 13 C chemical shifts) (Goodarzi, Freitas, & Ramalho, 2009) and agrochemistry (in the modeling of the phytotoxicity and soil sorption profiles of herbicides) may be found in the literature (Bitencourt & Freitas, 2008;Freitas, Matias, Macedo, Freitas, & Venturin, 2013;Goodarzi & Freitas, 2010b). These results demonstrate the utility of these MDs in codifying relevant chemical structure information.…”